Crossmark

Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?

Published Online: 2023-04-11

Published Print: 2023-07

Authors

Desai, Aakash

Smith, Caleb J. https://orcid.org/0000-0003-1974-0175
West, Howard Jack
License Information

Text and Data Mining valid from 2023-04-11

Version of Record valid from 2023-04-11
More Information

Article History

First Online: 11 April 2023

Competing interests

: A.D. has been an advisory board member for Amgen, Foundation Medicine and Sanofi. H.J.W. has been an advisory board member for Amgen, AstraZeneca, Boehringer–Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech/Roche, Merck, Mirati, Regeneron, Summit Therapeutics and Takeda. C.J.S. declares no competing interests.

Document is current